Mylan Pharmaceuticals, Inc. v. United Steel, Paper & Forestry, Rubber, Manufacturing, Energy, Allied Industrial & Service Workers International Union, Local 8-957

548 F. Supp. 2d 252, 2008 U.S. Dist. LEXIS 17988
CourtDistrict Court, N.D. West Virginia
DecidedMarch 6, 2008
DocketCivil Action 1:07CV4
StatusPublished

This text of 548 F. Supp. 2d 252 (Mylan Pharmaceuticals, Inc. v. United Steel, Paper & Forestry, Rubber, Manufacturing, Energy, Allied Industrial & Service Workers International Union, Local 8-957) is published on Counsel Stack Legal Research, covering District Court, N.D. West Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Mylan Pharmaceuticals, Inc. v. United Steel, Paper & Forestry, Rubber, Manufacturing, Energy, Allied Industrial & Service Workers International Union, Local 8-957, 548 F. Supp. 2d 252, 2008 U.S. Dist. LEXIS 17988 (N.D.W. Va. 2008).

Opinion

MEMORANDUM OPINION AND ORDER

IRENE M. KEELEY, District Judge.

Before the Court are the parties’ cross motions for summary judgment. The plaintiff, Mylan Pharmaceuticals, Inc. (“Mylan”), is a developer, manufacturer and distributer of generic prescription drugs. The defendant, United Steel, Paper and Forestry, Rubber, Manufacturing, Energy, Allied Industrial and Service Workers International Union, Local 8-957 (the “Union”), represents the production employees at Mylan’s facility in Morgan-town, West Virginia.

In this lawsuit, Mylan seeks to vacate an arbitration award (“the Award”) reinstating Grievant and collective bargaining unit member, John Jones (“Jones”). The Union seeks to enforce the Award, which held that Mylan discharged Jones without just cause, in violation of the parties’ April 8, 2002 Collective Bargaining Agreement (“CBA”). The Award further ordered that Jones be reinstated subject to a disciplinary suspension of ten working days. For the reasons discussed below, the Court DENIES Mylan’s motion for summary judgment, GRANTS the Union’s motion for summary judgment, and UPHOLDS the Award.

I. Factual Background

In January 2000, Jones began working for Mylan in the Granulation Department as a Compactor-Fitzmill Operator. In this position, he fan sieve tests to determine the density of raw drug materials that are later compacted into tablets or capsules. 1 On April 25, 2005, when the results of one of these sieve tests failed to conform to pre-established parameters, Jones manipulated the results and recorded false numbers on a data sheet. After a supervisor noticed a problem with the test, Jones admitted that he had altered the numbers, and further disclosed that he had manipu *256 lated data approximately fifty times in the past. 2

On May 20, 2005, approximately one month after discovering that Jones had manipulated data, Mylan discharged him for violating Mylan’s Code of Conduct and also for violating the Food and Drug Administration’s (“FDA”) Code of Federal Regulations.

Under Mylan’s Code of Conduct, violations are categorized into four levels, with Group IV constituting the most serious offenses. Mylan charged Jones with the following violations:

Group TV, Rule 1 — Falsification of any records, reports, accident or insurance claims, medical excuses, etc.;
Group III, Rule 7 — Conduct which interferes with or poses a conflict of interest with the efficient, orderly or safe operation of the Company’s business; Group II, Rule 2 — Failure to follow Standard Operating Procedures (specifically SOP-1400 and 1401), Good Manufacturing Practices, or Good Laboratory Practices; and
Group I, Rule 11 — Failure to satisfactorily carry out the duties and responsibilities of assignments.

The Code of Conduct also provides for progressive disciplinary responses, called “corrective measures,” that increase in punitive impact at each offense level. For example, a first-time Group I violation warrants a written warning; the corrective measure for a first-time violation in Group IV, on the other hand, includes “suspension of employment for up to forty-five (45) work days or termination of employment, depending upon the nature and character of the prohibited conduct.”

Mylan promulgated its Code of Conduct pursuant to authority reserved to it by the parties’ CBA. Under the CBA, Mylan has the exclusive right to manage its business and direct and control its workforce so long as this right is exercised in a manner consistent with other provisions of the CBA. Mylan, however, may only discharge an employee for just cause.

The CBA further provides that any claims of improper discipline or discharge must be resolved pursuant to a grievance procedure and, ultimately, may be determined by final and binding arbitration. In reviewing an action, the arbitrator’s authority under the CBA is confined to “application and interpretation of the specified provision or provisions of the agreement at issue,” and the arbitrator cannot “alter, amend, delete or add” to any of the terms of the CBA.

After Mylan discharged Jones, the Union initiated a grievance process in which it argued that, by terminating Jones for a first-time offense, Mylan had subjected him to disparate treatment. Arbitrator David Petersen held a hearing in this matter on November 10, 2005 and issued a final decision on November 28, 2006.

At the arbitration hearing, Mylan established that Jones’ manipulation of data violated not only its own Standard Operating Procedures (“SOPs”) but also the industry’s Good Manufacturing Practices (“GMPs”), which are determined by the FDA. Through the testimony of Paul Vo-gel (“Vogel”), a former senior FDA employee and expert on FDA policies and procedures, it established that federal law prohibits adulterating a pharmaceutical and that a drug is considered adulterated *257 if it is not manufactured in conformance with GMPs. Mylan further established that the FDA may sanction a manufacturer who is not in compliance with GMPs by issuing a warning letter, by asking a federal court to seize the goods, or by seeking an injunction to shut down the company.

On cross-examination, Vogel admitted that the FDA does not discipline manufacturing employees directly, nor does it mandate what type of discipline an employee found to have violated a GMP should receive. Rather, the FDA requires only that an employer take appropriate corrective action.

Through employee disciplinary records, at the arbitration the Union documented that no other collective bargaining unit worker at Mylan had ever been successfully discharged for a first-time violation, even for a violation of a Group IV rule.

In his ruling, Arbitrator Petersen considered Mylan’s Code of Conduct and its range of corrective measures, noting that, in the Introduction to its Code of Conduct, Mylan states that it is “the Company’s intention to enforce this Code in a reasonable and fair manner that will not only protect its legitimate business interests, but also the legitimate interests and concerns of its employees.” He observed that, in more than five years of service at Mylan prior to this incident, Jones had never been disciplined. He also recognized that Mylan had offered evidence that it had previously successfully discharged an employee without strictly following progressive disciplinary procedures, but noted that, unlike Jones, that employee had a disciplinary history.

Thus, because it “was not shown that the Company had ever imposed discharge for a first occurrence of a rule violation where the employee had significant service and had never previously been disciplined for any offense,” and because “it was not shown that Grievant’s misconduct was so egregious that it warranted summary discharge regardless of his previously clean discipline record,” the Arbitrator concluded that Mylan had not enforced the Code of Conduct in a reasonable and fair manner and had discharged Jones without just cause. He thus awarded Jones reinstatement, subject to a suspension of ten working days.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United Steelworkers v. American Manufacturing Co.
363 U.S. 564 (Supreme Court, 1960)
United Steelworkers v. Enterprise Wheel & Car Corp.
363 U.S. 593 (Supreme Court, 1960)
Union Pacific Railroad v. Sheehan
439 U.S. 89 (Supreme Court, 1979)

Cite This Page — Counsel Stack

Bluebook (online)
548 F. Supp. 2d 252, 2008 U.S. Dist. LEXIS 17988, Counsel Stack Legal Research, https://law.counselstack.com/opinion/mylan-pharmaceuticals-inc-v-united-steel-paper-forestry-rubber-wvnd-2008.